Celltrion’s dolutegravir/lamivudine/tenofovir tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
PQ-IVD Technical Specifications: Consultation for IVDs to detect SARS-CoV-2 nucleic acid (closed systems and open platforms) and rapid diagnostic tests (RDTs) to detect SARS-CoV-2 antigen for professional use and/or self-testing
IVD
WHO has been developing PQ technical specifications for IVDs to detect SARS-CoV-2 nucleic acid (closed systems and open platforms) and
PQ-IVD Technical Specifications: Consultation for hemoglobin POC analyzers and revision of malaria RDTs performance study requirements
IVD
The PQT In Vitro Diagnostics Assessment team held a two day consultation meeting with experts in Geneva to review and finalize proposed performance study requirements for WHO prequalification
First pilot assessment session for in vitro diagnostics
IVD
The PQT-IVD team held a joint assessment session from 5-9 June in Geneva session to pilot a new assessment model whereby assessors meet for a week during which they work in groups to assess product
Two PQT Medicines workshops for manufacturers
M
The PQT Medicines 6th Annual Medicines Quality Workshop for Manufacturers will take place from 25 to 28 September 2023.